Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
Chemotherapy has been the main treatment option for multiple myeloma for several decades. However, a considerable increase in the life expectancy was observed in multiple myeloma patients when thalidomide, bortezomib and lenalidomide had been introduced into clinical practice. Nevertheless, the dise...
Saved in:
| Main Author: | OM Votyakova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2016-10-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/en/elotuzumab-for-treatment-of-multiple-myeloma-literature-review/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01) -
New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review
by: OM Votyakova
Published: (2017-10-01) -
ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING
by: Masafumi Taniwaki, et al.
Published: (2018-02-01) -
Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01) -
Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series
by: Tomoki Suichi, et al.
Published: (2025-12-01)